30 filings
Page 2 of 2
8-K
ya3wv1wscj i5x8
11 Aug 22
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
4:25pm
8-K
5djeyay xie33mme9hv
30 Jun 22
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle
7:31am
8-K
lp8x 3bdb5ut
22 Jun 22
Regulation FD Disclosure
5:02pm
8-K
bju4y
15 Jun 22
Submission of Matters to a Vote of Security Holders
5:02pm
8-K
0xf9o gr6
26 May 22
Regulation FD Disclosure
6:04pm
8-K
4ew74
18 May 22
Entry into a Material Definitive Agreement
4:06pm
8-K
k0rwjes17hqtgxyuh e6
12 May 22
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
4:29pm
8-K
gjll6fpebvcy2o7tgxg
23 Mar 22
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
4:21pm
8-K
fgbpp
24 Nov 21
Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
4:15pm
8-K
psvhtg0f
2 Nov 21
Amendments to Articles of Incorporation or Bylaws
4:06pm